The reason for asking this is I am only starting to appreciate what others have previously pointed out, that this is a study that has been set up to provide 'evidence' for the care of people with ME/CFS and Long Covid in the future, yet apparently it will only include a relatively small number (250 attending clinics plus whoever will stick with the godawful ELAROS/AUTONOM-E platform from the wider community) of people with ME/CFS, and that small number is likely to be those more mildly affected and who have been affected for a relatively shorter amount of time. This will inevitably lead to a biased view of what allegedly works or is needed.
In the
entry for HERITAGE in the clinical study registry they say
"The study will enrol approximately 3,000 individuals with LC and/or ME/CFS. Allowing for an estimated 50% attrition rate, we anticipate that over 1,500 participants will complete the 12‑month longitudinal follow‑up, providing robust trajectories of symptoms, functioning, and service use over time. "
so their real anticipated number of participants is half of their headline number, so there will be heavy survivorship bias excluding long term and more seriously affected participants.